143 related articles for article (PubMed ID: 15811552)
1. Expression profiling with progression of dystrophic change in dysferlin-deficient mice (SJL).
Suzuki N; Aoki M; Hinuma Y; Takahashi T; Onodera Y; Ishigaki A; Kato M; Warita H; Tateyama M; Itoyama Y
Neurosci Res; 2005 May; 52(1):47-60. PubMed ID: 15811552
[TBL] [Abstract][Full Text] [Related]
2. The differential gene expression profiles of proximal and distal muscle groups are altered in pre-pathological dysferlin-deficient mice.
von der Hagen M; Laval SH; Cree LM; Haldane F; Pocock M; Wappler I; Peters H; Reitsamer HA; Hoger H; Wiedner M; Oberndorfer F; Anderson LV; Straub V; Bittner RE; Bushby KM
Neuromuscul Disord; 2005 Dec; 15(12):863-77. PubMed ID: 16288871
[TBL] [Abstract][Full Text] [Related]
3. Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency.
Ho M; Post CM; Donahue LR; Lidov HG; Bronson RT; Goolsby H; Watkins SC; Cox GA; Brown RH
Hum Mol Genet; 2004 Sep; 13(18):1999-2010. PubMed ID: 15254015
[TBL] [Abstract][Full Text] [Related]
4. Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer.
Lostal W; Bartoli M; Bourg N; Roudaut C; Bentaïb A; Miyake K; Guerchet N; Fougerousse F; McNeil P; Richard I
Hum Mol Genet; 2010 May; 19(10):1897-907. PubMed ID: 20154340
[TBL] [Abstract][Full Text] [Related]
5. The distribution and characterization of skeletal muscle lesions in dysferlin-deficient SJL and A/J mice.
Kobayashi K; Izawa T; Kuwamura M; Yamate J
Exp Toxicol Pathol; 2010 Sep; 62(5):509-17. PubMed ID: 19615872
[TBL] [Abstract][Full Text] [Related]
6. Changes in skeletal muscle expression of AQP1 and AQP4 in dystrophinopathy and dysferlinopathy patients.
Au CG; Butler TL; Egan JR; Cooper ST; Lo HP; Compton AG; North KN; Winlaw DS
Acta Neuropathol; 2008 Sep; 116(3):235-46. PubMed ID: 18392839
[TBL] [Abstract][Full Text] [Related]
7. Defective membrane repair in dysferlin-deficient muscular dystrophy.
Bansal D; Miyake K; Vogel SS; Groh S; Chen CC; Williamson R; McNeil PL; Campbell KP
Nature; 2003 May; 423(6936):168-72. PubMed ID: 12736685
[TBL] [Abstract][Full Text] [Related]
8. Characterization of lobulated fibers in limb girdle muscular dystrophy type 2A by gene expression profiling.
Keira Y; Noguchi S; Kurokawa R; Fujita M; Minami N; Hayashi YK; Kato T; Nishino I
Neurosci Res; 2007 Apr; 57(4):513-21. PubMed ID: 17258832
[TBL] [Abstract][Full Text] [Related]
9. SJL dystrophic mice express a significant amount of human muscle proteins following systemic delivery of human adipose-derived stromal cells without immunosuppression.
Vieira NM; Bueno CR; Brandalise V; Moraes LV; Zucconi E; Secco M; Suzuki MF; Camargo MM; Bartolini P; Brum PC; Vainzof M; Zatz M
Stem Cells; 2008 Sep; 26(9):2391-8. PubMed ID: 18583542
[TBL] [Abstract][Full Text] [Related]
10. Lipid accumulation in dysferlin-deficient muscles.
Grounds MD; Terrill JR; Radley-Crabb HG; Robertson T; Papadimitriou J; Spuler S; Shavlakadze T
Am J Pathol; 2014 Jun; 184(6):1668-76. PubMed ID: 24685690
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of the dysferlin skeletal muscle promoter.
Foxton RM; Laval SH; Bushby KM
Eur J Hum Genet; 2004 Feb; 12(2):127-31. PubMed ID: 14560310
[TBL] [Abstract][Full Text] [Related]
12. Common pathological mechanisms in mouse models for muscular dystrophies.
Turk R; Sterrenburg E; van der Wees CG; de Meijer EJ; de Menezes RX; Groh S; Campbell KP; Noguchi S; van Ommen GJ; den Dunnen JT; 't Hoen PA
FASEB J; 2006 Jan; 20(1):127-9. PubMed ID: 16306063
[TBL] [Abstract][Full Text] [Related]
13. Intracellular accumulation and reduced sarcolemmal expression of dysferlin in limb--girdle muscular dystrophies.
Piccolo F; Moore SA; Ford GC; Campbell KP
Ann Neurol; 2000 Dec; 48(6):902-12. PubMed ID: 11117547
[TBL] [Abstract][Full Text] [Related]
14. Dysfunction of dysferlin-deficient hearts.
Wenzel K; Geier C; Qadri F; Hubner N; Schulz H; Erdmann B; Gross V; Bauer D; Dechend R; Dietz R; Osterziel KJ; Spuler S; Ozcelik C
J Mol Med (Berl); 2007 Nov; 85(11):1203-14. PubMed ID: 17828519
[TBL] [Abstract][Full Text] [Related]
15. Loss of podocyte dysferlin expression is associated with minimal change nephropathy.
Izzedine H; Brocheriou I; Eymard B; Le Charpentier M; Romero NB; Lenaour G; Bourry E; Deray G
Am J Kidney Dis; 2006 Jul; 48(1):143-50. PubMed ID: 16797397
[TBL] [Abstract][Full Text] [Related]
16. Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B.
Bittner RE; Anderson LV; Burkhardt E; Bashir R; Vafiadaki E; Ivanova S; Raffelsberger T; Maerk I; Höger H; Jung M; Karbasiyan M; Storch M; Lassmann H; Moss JA; Davison K; Harrison R; Bushby KM; Reis A
Nat Genet; 1999 Oct; 23(2):141-2. PubMed ID: 10508505
[No Abstract] [Full Text] [Related]
17. A naturally occurring human minidysferlin protein repairs sarcolemmal lesions in a mouse model of dysferlinopathy.
Krahn M; Wein N; Bartoli M; Lostal W; Courrier S; Bourg-Alibert N; Nguyen K; Vial C; Streichenberger N; Labelle V; DePetris D; Pécheux C; Leturcq F; Cau P; Richard I; Lévy N
Sci Transl Med; 2010 Sep; 2(50):50ra69. PubMed ID: 20861509
[TBL] [Abstract][Full Text] [Related]
18. Dysferlin expression after normal myoblast transplantation in SCID and in SJL mice.
Leriche-Guérin K; Anderson LV; Wrogemann K; Roy B; Goulet M; Tremblay JP
Neuromuscul Disord; 2002 Feb; 12(2):167-73. PubMed ID: 11738359
[TBL] [Abstract][Full Text] [Related]
19. Painful enlargement of the calf muscles in limb girdle muscular dystrophy type 2B (LGMD2B) with a novel compound heterozygous mutation in DYSF.
Diers A; Carl M; Stoltenburg-Didinger G; Vorgerd M; Spuler S
Neuromuscul Disord; 2007 Feb; 17(2):157-62. PubMed ID: 17129727
[TBL] [Abstract][Full Text] [Related]
20. Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies.
Nguyen K; Bassez G; Bernard R; Krahn M; Labelle V; Figarella-Branger D; Pouget J; Hammouda el H; Béroud C; Urtizberea A; Eymard B; Leturcq F; Lévy N
Hum Mutat; 2005 Aug; 26(2):165. PubMed ID: 16010686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
